PRNewsWire
12 Oct 2026, 21:34 UTC · 1h ago
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
Impact · against what's priced in
Aardvark Therapeutics faces potential downward pressure as a securities fraud lawsuit alleges the company misled investors regarding the safety and commercial viability of its lead candidate, ARD-101. While the lawsuit itself may be known, the imminent lead plaintiff deadline increases immediate visibility of the legal risk.
- AARD−0.40
No priced-in read yet





